Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
Agios Pharmaceuticals (NASDAQ: AGIO), a company focused on cellular metabolism and pyruvate kinase activation for rare diseases, has announced its upcoming participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for June 9, 2025, at 8:40 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A replay will remain available on the company's website for a minimum of two weeks after the presentation.
Agios Pharmaceuticals (NASDAQ: AGIO), un'azienda specializzata nel metabolismo cellulare e nell'attivazione della piruvato chinasi per malattie rare, ha annunciato la sua prossima partecipazione alla 46ª Conferenza Annuale Globale sulla Sanità di Goldman Sachs. La presentazione è prevista per il 9 giugno 2025 alle 8:40 a.m. ET. Investitori e interessati potranno seguire la diretta streaming nella sezione Investitori del sito web di Agios, nella pagina "Eventi e Presentazioni". Una registrazione sarà disponibile sul sito aziendale per almeno due settimane dopo la presentazione.
Agios Pharmaceuticals (NASDAQ: AGIO), una empresa centrada en el metabolismo celular y la activación de la piruvato quinasa para enfermedades raras, ha anunciado su próxima participación en la 46ª Conferencia Anual Global de Salud de Goldman Sachs. La presentación está programada para el 9 de junio de 2025 a las 8:40 a.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores en el sitio web de Agios, bajo "Eventos y Presentaciones". Una repetición estará disponible en la página web de la empresa durante al menos dos semanas después de la presentación.
Agios Pharmaceuticals (NASDAQ: AGIO)는 희귀 질환을 위한 세포 대사 및 피루브산 키나제 활성화에 중점을 둔 회사로, 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여할 예정임을 발표했습니다. 발표는 2025년 6월 9일 오전 8시 40분(동부시간)에 예정되어 있습니다. 투자자 및 관심 있는 분들은 Agios 웹사이트의 투자자 섹션 내 '이벤트 및 발표'에서 생중계 웹캐스트에 접속할 수 있습니다. 발표 후 최소 2주간 회사 웹사이트에서 다시보기 서비스를 이용할 수 있습니다.
Agios Pharmaceuticals (NASDAQ : AGIO), une entreprise spécialisée dans le métabolisme cellulaire et l'activation de la pyruvate kinase pour les maladies rares, a annoncé sa prochaine participation à la 46e conférence annuelle mondiale sur la santé de Goldman Sachs. La présentation est prévue pour le 9 juin 2025 à 8h40 (heure de l'Est). Les investisseurs et parties intéressées peuvent accéder à la diffusion en direct via la section Investisseurs du site web d'Agios, sous « Événements et Présentations ». Une rediffusion restera disponible sur le site de l'entreprise pendant au moins deux semaines après la présentation.
Agios Pharmaceuticals (NASDAQ: AGIO), ein Unternehmen, das sich auf Zellstoffwechsel und Pyruvatkinase-Aktivierung bei seltenen Krankheiten spezialisiert hat, hat seine bevorstehende Teilnahme an der 46. jährlichen globalen Gesundheitskonferenz von Goldman Sachs angekündigt. Die Präsentation ist für den 9. Juni 2025 um 8:40 Uhr ET geplant. Investoren und Interessierte können den Live-Webcast über den Investor-Bereich der Agios-Website unter "Veranstaltungen & Präsentationen" verfolgen. Eine Wiederholung wird mindestens zwei Wochen nach der Präsentation auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 8:40 a.m. ET.
The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When is Agios Pharmaceuticals (AGIO) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I watch Agios Pharmaceuticals' (AGIO) Goldman Sachs conference presentation?
How long will Agios Pharmaceuticals' (AGIO) Goldman Sachs conference presentation replay be available?
What is Agios Pharmaceuticals' (AGIO) main business focus?
